coronary-artery-disease
(8)
Cleerly
Cleerly is a Denver-based digital healthcare company using FDA-cleared artificial intelligence to analyze coronary CT scans and non-invasively measure plaque, stenosis and the likelihood of ischemia in the heart's arteries. Founded in 2017 by cardiologist James K. Min, the company builds machine-learning software that turns a routine CCTA scan into a quantitative, vessel-by-vessel picture of coronary artery disease - aiming to catch atherosclerosis earlier and help physicians prevent heart attacks rather than react to them.
DexaFit
DexaFit is a health-testing company that turns a quick, low-radiation full-body DXA scan into a broad picture of a person's health - body composition, bone density, visceral fat and metabolic markers. Its AI arm, DexaFit Dx, layers machine learning on top of those same scans to screen for major chronic diseases such as coronary artery disease and type 2 diabetes, aiming to catch them early and non-invasively. Founded in Chicago in 2011 and now operating dozens of centers, DexaFit pairs in-person testing with an app that translates results into longevity scores, disease-risk estimates and trackable goals.
Heartflow
Heartflow is a Silicon Valley medical technology company that uses AI and computational fluid dynamics to turn a standard coronary CT scan into a personalized, color-coded 3D model of a patient's heart. Its FFRCT, Plaque and RoadMap analyses help cardiologists diagnose and manage coronary artery disease non-invasively, reducing the need for invasive angiograms. Founded in 2007 and headquartered in San Francisco, Heartflow has analyzed hundreds of thousands of patients across more than 1,500 U.S. hospitals and went public on the Nasdaq (HTFL) in August 2025.
Allelica, Inc.
Allelica is a genomics software company building the tools that move polygenic risk scores (PRS) out of the research lab and into routine clinical care. Its cloud platform lets labs and health systems develop, validate, and apply PRS across multiple ancestries, and its clinical test AbsoluteDx combines rare-variant (monogenic) and genome-wide (polygenic) risk in a single report. The company's stated priority is equity - building risk scores that work for patients regardless of genetic ancestry - and its multi-ancestry coronary artery disease work was cited in the 2026 ACC/AHA cardiovascular prevention guidelines.
Elixir Medical Corporation
Elixir Medical Corporation is a privately held Milpitas, California medical device company building implantable technologies to treat coronary and peripheral artery disease. Its flagship DynamX Coronary Bioadaptor is a metal implant with a resorbable polymer coating that dissolves over roughly six months, 'uncaging' the artery so the vessel can pulse and move naturally rather than remaining permanently rigid like a conventional stent. Founded in 2005 by Motasim Sirhan, Elixir has produced a lineage of coronary devices - the DESolve bioresorbable scaffold, the DESyne family of drug-eluting stents, the LithiX intravascular lithotripsy system, and the DynamX bioadaptor - and has reported two consecutive randomized trials showing reduced long-term cardiac event rates versus current drug-eluting stents.
CorVista Health
CorVista Health is a medical technology company applying machine learning to cardiovascular diagnostics. Its FDA-cleared CorVista System is a non-invasive, point-of-care device that captures cardiac and hemodynamic signals and analyzes them in the cloud to assess the likelihood of coronary artery disease and pulmonary hypertension - delivering results in minutes, without radiation, contrast, injections, fasting, or exercise. The company aims to shorten the path from symptoms to diagnosis so patients can be treated earlier.
AngioWave Imaging
AngioWave Imaging is a Massachusetts-based medical AI company building post-processing software that sharpens fluoroscopic angiograms in the cardiac catheterization lab. Its FDA 510(k)-cleared AngioWaveNet uses a spatiotemporal, convolutional deep neural network (branded STEP) to reveal blood-vessel detail that is hard to see on the raw angiogram, helping interventional cardiologists diagnose and treat coronary artery disease. The software runs on top of any existing fluoroscopy system, requiring no new hardware.
Intravascular Imaging Incorporated (i3)
Intravascular Imaging Incorporated (i3) is a Wilton, Connecticut medical device company building a next-generation coronary imaging catheter. Its 3-French NIRF-IVUS catheter fuses intravascular ultrasound (IVUS), the clinical standard for guiding stent placement, with near-infrared fluorescence (NIRF) molecular imaging in a single device. The combination lets cardiologists see not just the anatomy of a coronary artery but the biology inside it - plaque inflammation, arterial dissections, transplant vasculopathy, and fibrin in unhealed stents. Spun out of work at Massachusetts General Hospital/Harvard Medical School and the Technical University of Munich, i3 aims to upgrade percutaneous coronary intervention (PCI) by helping doctors look beyond anatomy.